Congratulations to BoardProspects Member Thorkil Kastberg Christensen on His Election to the Board of SAB Biotherapeutics
BoardProspects would like to congratulate Member Thorkil Kastberg Christensen on his election to the Board of Directors of SAB Biotherapeutics. Mr. Christensen is the former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about US$40 billion. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics.